3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Phase 2
1
Status
Recruiting
3
Terminated
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Hepatocellular
36
Carcinoma, Non-Small-Cell Lung
17
Small Cell Lung Carcinoma
16
Neoplasms
14
Lung Neoplasms
13
Breast Neoplasms
7
Melanoma
6
Colorectal Neoplasms
6
Carcinoma, Renal Cell
6
Squamous Cell Carcinoma of Head and Neck
5
Liver Neoplasms
5
Triple Negative Breast Neoplasms
4
Prostatic Neoplasms
4
Neoplasm Metastasis
4
Head and Neck Neoplasms
4
Glioblastoma
4
Endometrial Neoplasms
4
Sarcoma
3
Recurrence
3
Neoplasms by Site
3
Neoplasms by Histologic Type
3
Carcinoma, Transitional Cell
3
Carcinoma, Squamous Cell
3
Uterine Cervical Neoplasms
2
Urogenital Neoplasms
2
Small Cell Lung Cancer Extensive Stage
2
Sarcoma, Alveolar Soft Part
2
Ovarian Neoplasms
2
Osteosarcoma
2
Mesothelioma, Malignant
2
Interventions
atezolizumab
3
fludarabine
2
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
Vemurafenib
2
Pemetrexed
2
Nivolumab
2
Cisplatin
2
spartalizumab
1
repotrectinib
1
pertuzumab
1
lutetium Lu 177 dotatate
1
gilteritinib
1
enzalutamide
1
durvalumab
1
copper dotatate CU-64
1
cemiplimab
1
Trastuzumab
1
Sodium Chloride
1
Radiotherapy
1
Radiosurgery
1
Mitomycin
1
Lutetium-177
1
Lutetium
1
Injections
1
Idarubicin
1
HuMax-IL8
1
Granulocyte Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms by Histologic Type
×
atezolizumab
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770102
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled
NCT06463665
2025-09-26
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled